ALK-Abelló A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALK-B.CO research report →
About the company
ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods.
- CEO
- Peter Halling
- IPO
- 2000
- Employees
- 2,736
- HQ
- Horsholm, DK
Price Chart
- Market Cap
- $56.73B
- P/E
- 44.37
- P/S
- 8.65
- P/B
- 8.64
- EV/EBITDA
- 26.28
- Div Yield
- 0.63%
- Gross Margin
- 67.76%
- Op Margin
- 26.73%
- Net Margin
- 19.51%
- ROE
- 20.45%
- ROIC
- 16.25%
- Revenue
- $6.31B · 14.00%
- Net Income
- $1.20B · 46.87%
- EPS
- $5.40 · 46.74%
- Op Income
- $1.66B
- FCF YoY
- 61.70%
- 52W High
- $271.40
- 52W Low
- $172.40
- 50D MA
- $249.23
- 200D MA
- $224.68
- Beta
- 0.70
- Avg Volume
- 211.90K
Get TickerSpark's AI analysis on ALK-B.CO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALK-B.CO coverage
Recent articles, reports, and earnings notes.
No research on ALK-B.CO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALK-B.CO report →Similar companies
Peers in the same neighborhood.